Latest filings (excl ownership)
425
Business combination disclosure
25 Apr 24
8-K
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
25 Apr 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Departure of Directors or Certain Officers
23 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
425
Business combination disclosure
3 Apr 24
8-K
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
3 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
ARCA biopharma Announces 2023 Financial Results
1 Feb 24
10-K
2023 FY
Annual report
1 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
ARS
2022 FY
Annual report to shareholders
19 Dec 23
DEFA14A
Additional proxy soliciting materials
19 Dec 23
DEF 14A
Definitive proxy
19 Dec 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
8-K
ARCA biopharma Announces Third Quarter 2023 Financial Results
18 Oct 23
10-Q
2023 Q3
Quarterly report
18 Oct 23
8-K
ARCA biopharma Announces Second Quarter 2023 Financial Results
21 Jul 23
10-Q
2023 Q1
Quarterly report
21 Jul 23
8-K
ARCA biopharma Announces First Quarter 2023 Financial Results
24 Apr 23
10-Q
2023 Q1
Quarterly report
24 Apr 23
8-K
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
24 Feb 23
10-K
2022 FY
Annual report
24 Feb 23
8-K
Departure of Directors or Certain Officers
13 Feb 23
8-K
JaMES FLYNN joins arca biopharma board of directors
19 Dec 22
8-K
Departure of Directors or Certain Officers
9 Dec 22
DEFA14A
Additional proxy soliciting materials
3 Nov 22
DEF 14A
Definitive proxy
3 Nov 22
8-K
ARCA biopharma Announces Third Quarter 2022 Financial Results
28 Oct 22
10-Q
2022 Q3
Quarterly report
28 Oct 22
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
20 Oct 22
8-K
ARCA biopharma Announces Second Quarter 2022 Financial Results
2 Aug 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
8-K
Jacob ma-weaver joins arca biopharma board of DIRECTORS
21 Jun 22
8-K
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
5 May 22
8-K
ARCA biopharma Announces First Quarter 2022 Financial Results
2 May 22
10-Q
2022 Q1
Quarterly report
2 May 22
8-K
ARCA biopharma Establishes Special Committee of the Board of Directors
18 Apr 22
Latest ownership filings
SC 13G
Venrock Healthcare Capital Partners III, L.P.
29 Apr 24
SC 13G
Allostery Investments LP
15 Apr 24
SC 13G
JANUS HENDERSON GROUP PLC
11 Apr 24
SC 13G
Avidity Partners Management LP
9 Apr 24
SC 13G/A
Western Standard LLC
5 Apr 24
SC 13D
Adage Capital Management, L.P.
5 Apr 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Jacob Ma-Weaver
31 Jan 24
4
Anders D Hove
31 Jan 24
4
DANIEL J MITCHELL
31 Jan 24
4
James P Flynn
31 Jan 24
4
ROBERT E CONWAY
31 Jan 24
4
Linda Grais
31 Jan 24
4
Raymond L. Woosley
31 Jan 24
SC 13G
Western Standard LLC
11 Sep 23
SC 13G/A
BML Investment Partners, L.P.
8 Feb 23
4
Jacob Ma-Weaver
19 Dec 22
4
Raymond L. Woosley
19 Dec 22
4
DANIEL J MITCHELL
19 Dec 22
4
Linda Grais
19 Dec 22
4
Anders D Hove
19 Dec 22
4
ROBERT E CONWAY
19 Dec 22
4
James P Flynn
19 Dec 22
3
James P Flynn
19 Dec 22
4
Thomas A Keuer
9 Dec 22
4
C. Jeffrey Dekker
9 Dec 22
4
Change in insider ownership
8 Jul 22
3
Initial statement of insider ownership
8 Jul 22
SC 13D/A
Funicular Funds, LP
8 Jul 22
4
Jacob Ma-Weaver
21 Jun 22
3
Jacob Ma-Weaver
21 Jun 22
SC 13D/A
Funicular Fund, LP
21 Jun 22
SC 13D/A
Ma-Weaver Jacob
27 May 22
4
Jacob Ma-Weaver
25 May 22
4
Jacob Ma-Weaver
20 May 22
4
Jacob Ma-Weaver
16 May 22
4
Jacob Ma-Weaver
11 May 22
SC 13D/A
Funicular Fund, LP
11 May 22
4
Jacob Ma-Weaver
9 May 22
4
Jacob Ma-Weaver
2 May 22